CDT Equity Inc. develops and repositions biopharmaceutical assets through a data-driven model that combines licensed clinical compounds, solid-form chemistry, cocrystal intellectual property and out-licensing. News about CDT commonly covers its AZD1656, AZD5658 and AZD5904 assets, patent filings, therapeutic-indication analysis, and programs spanning autoimmune disorders, idiopathic male infertility, dermatology, oncology, rare disease and animal health.
Company updates also include CDT's 20% equity interest in Sarborg Limited, whose Signature Agent, Multi-Agent and Signature Intelligence platforms are used for disease mapping and therapeutic-opportunity identification. Other recurring items include stockholder votes, Nasdaq capital-structure actions, warrants and equity financing arrangements.
CDT Equity (CDT) will implement a 1-for-25 reverse stock split of its common stock on September 28, 2026. The board approved the split to ensure continued compliance with Nasdaq’s bid-price rule. At 5:00 p.m. Eastern Time, every 25 issued and outstanding common shares will become one share.
Split-adjusted trading on the Nasdaq Capital Market is expected to begin at market open on September 29 under the existing CDT symbol. The split will reduce outstanding common shares to approximately 1,013,515. Holders otherwise entitled to fractional shares will receive a proportional cash payment.
CDT (CDT) announced a partnership with preclinical dermatology CRO QIMA Life Sciences on 18 September 2026 to evaluate several CDT assets for autoimmune skin diseases using human skin samples from healthy donors and patients.
Initial work will focus on tapinarof (VTAMA®), already approved for plaque psoriasis and atopic dermatitis in the US and Japan. CDT has built an intellectual property portfolio around tapinarof, including solid-form and method-of-use patents for combinations with other known drugs. QIMA will test these novel tapinarof combinations in psoriatic patient skin to work towards a second-generation product with enhanced efficacy and patient benefits and to support potential licensing discussions.
CDT also plans to assess its proprietary tapinarof combinations in vitiligo, which affects an estimated 0.5%–2.0% of the global population. The vitiligo drug market was about US$2.6 billion in 2025 and is projected to reach US$6.6 billion by 2030.
CDT Equity (CDT) reports portfolio company Sarborg has successfully applied its patented Signature Intelligence and quantum computing models to mental health and neuropsychiatric drug discovery.
Sarborg has built a proprietary database of disease signatures, including depression, bipolar disorder, anxiety and schizophrenia, and has used its models to identify potential relationships between these signatures and therapeutic candidates. CDT states this demonstrates broader potential for Sarborg’s technology across unmet medical needs. Sarborg is in discussions with pharmaceutical and biotechnology companies, academic institutions and research organisations about potential applications and collaborations.
CDT holds 1,290 Sarborg shares, representing 22.7% of its issued share capital. Sarborg’s latest capital raise was priced at $125,000 per share, implying a fully diluted valuation of approximately $709 million.
CDT Equity (CDT) reported updated capital figures and confirmed its Nasdaq compliance status as of late August 2026.
After recent share issuances and exercises of pre-funded warrants, CDT had 13,693,866 shares of common stock issued and outstanding as of August 31, 2026. Based on that day’s closing share price, the company’s market capitalization was approximately $23.0 million. CDT’s stockholders’ equity, reported in its Form 10-Q for the quarter ended June 30, 2026, was approximately $103 million. The company also stated that, following these issuances and related corporate actions, it no longer has any outstanding deficiencies with The Nasdaq Stock Market.
CDT (Nasdaq: CDT) appointed co-founder James Bligh as Chief Executive Officer, succeeding Dr. Andrew Regan, who becomes CEO of Sarborg Limited. Bligh co-founded Conduit Pharmaceuticals (now CDT) in 2019 and has extensive experience in reverse takeovers, listings, IPOs, secondary fundraisings and M&A, as well as prior financial officer and board roles.
According to CDT, the appointment follows a period of strengthening the balance sheet, reducing the operating cost base and completing strategic investments. These include acquiring a significant stake in quantum signature intelligence company Sarborg and restructuring the company’s loan notes and funding facilities. CDT now holds a 22% strategic investment in Sarborg and plans to work closely with it as Sarborg develops its signature intelligence platform, expands its proprietary IP and advances its SarborgQ offering.
CDT (Nasdaq: CDT) reported that new solid forms and alternative crystal structures of its existing drug compounds exhibit enhanced physical properties, including stability, solubility and manufacturability, compared with existing forms. These solid forms fall under CDT’s Substance of Matter intellectual property and may enable new, patient-tailored formulations, potentially extending commercial lifespans.
Using Sarborg’s Signature Intelligence, CDT identified new potential uses for its assets, alone or with marketed drugs, and has filed patents covering these applications in diseases with limited treatment options. The company plans to test these findings in clinically relevant lab models, evaluate competitive differentiation of its solid forms, and assemble an AI-driven evidence and IP package aimed at supporting future partnering and out-licensing.
CDT (Nasdaq: CDT) has entered into a SAFE note with US-based peptide company Pep'd, giving CDT exposure to the expanding US peptide market. The SAFE will convert into Pep'd Safe Preferred Stock upon a future equity financing, using a $10 million valuation cap and Pep'd capitalization at that time.
According to CDT, the deal supports its strategy of backing science-driven, AI-enabled platforms in therapeutics discovery and development. Pep'd has launched its platform, begun generating revenue, and operates a vertically integrated model that combines telehealth, in-house research, and compounding. CDT views the SAFE as a capital-efficient way to participate in peptide sector growth. Pep'd is controlled by CDT CEO Dr. Andrew Regan, who is its sole shareholder.
CDT Equity (Nasdaq: CDT) agreed to increase its equity stake in agentic AI company Sarborg to 22.7% via a strategic transaction involving pre-funded warrants to purchase up to 12,131,770 CDT common shares, subject to shareholder approval on August 28, 2026.
According to CDT, the move follows Sarborg’s expansion of its Signature Intelligence platform into quantum computing through its SarborgQ division, new IP across pharmaceuticals, agriculture and technology, and a prior third‑party funding round implying a fully diluted valuation of about $638.3 million.
CDT (Nasdaq: CDT) reports that portfolio company Sarborg has filed a new patent application for a large set of field-deployable, two-component combination interventions for sugarcane cultivation, generated using its quantum-enabled PRISM platform.
According to Sarborg, the filing structures 606 field-applicable combinations into six application configurations based on growth stage, delivery route, dose, timing and agronomic target. The combinations were identified using PRISM’s cross-species connectivity engine, powered by SarborgQ, its quantum division. CDT, which acquired 1,020 Sarborg shares on February 20, 2026, representing 20% of Sarborg’s issued share capital at that time, views the patent filing as an important milestone in Sarborg’s Signature Intelligence platform and its extension beyond pharmaceuticals into agriculture.
CDT Equity (Nasdaq: CDT) has approved a 1-for-10 reverse stock split of its common stock to support continued compliance with Nasdaq’s bid-price rule. The split becomes effective on July 17, 2026 at 5:00 p.m. ET, with split-adjusted trading on Nasdaq beginning July 20, 2026 under the existing ticker CDT and a new CUSIP, 20678X601.
At the effective time, every 10 issued and outstanding shares will be combined into one share, with par value unchanged at $0.0001. Outstanding shares are expected to be reduced to approximately 631,077. Equity awards, convertible securities, warrants and plan reserves will be proportionally adjusted. No fractional shares will be issued; affected holders will receive cash instead. Continental Stock Transfer & Trust will act as exchange agent, and most shareholders will not need to take action.